These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 17686822)

  • 1. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
    J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
    Hurwitz HI; Saltz LB; Van Cutsem E; Cassidy J; Wiedemann J; Sirzén F; Lyman GH; Rohr UP
    J Clin Oncol; 2011 May; 29(13):1757-64. PubMed ID: 21422411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
    Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
    Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.
    Korswagen LA; Bartelds GM; Krieckaert CL; Turkstra F; Nurmohamed MT; van Schaardenburg D; Wijbrandts CA; Tak PP; Lems WF; Dijkmans BA; van Vugt RM; Wolbink GJ
    Arthritis Rheum; 2011 Apr; 63(4):877-83. PubMed ID: 21452312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of recombinant activated factor VII in randomized clinical trials.
    Levi M; Levy JH; Andersen HF; Truloff D
    N Engl J Med; 2010 Nov; 363(19):1791-800. PubMed ID: 21047223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
    Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
    J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
    Cortés J; Caralt M; Delaloge S; Cortes-Funes H; Pierga JY; Pritchard KI; Bollag DT; Miles DW
    Eur J Cancer; 2012 Mar; 48(4):475-81. PubMed ID: 22196033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. A randomized trial (FFAACS)].
    Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentré F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
    Therapie; 2000; 55(6):681-9. PubMed ID: 11234463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.